The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint. Cisco shares rise sharply after the dot-com darling shows off its AI credentials, while ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

When chip giant Nvidia (NVDA) shows interest in any company, analysts and investors take note. According to Nvidia’s most ...

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs ...

CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin ...

Krystal Biotech, a Pittsburgh-based gene therapy company, has picked up a key win across the Atlantic, securing UK regulatory ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...

Humacyte is cutting about a quarter of its workforce as it revamps its commercial strategy. Durham biotech's breakthrough ...

Yenssen Biotech opens international distributor recruitment for Dermlin wound healing series, Ulceloocin oral ulcer ...